The Evaluation of Efficacy and Safety of Rituximab in Refractory CIDP Patients With IgG4 Autoantibodies

Phase 2

Completed

• Conditions: Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
• Interventions: Biological: Rituximab (genetical recombination); Other: Placebo

• Registration Number: NCT03864185
• Lead Sponsor: Nagoya University

Brief Summary

To evaluate the efficacy and safety of rituximab (genetical recombination) intravenously administered to CIDP patients with positive or negative IgG4 autoantibody.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2019-02-19
• Study First Submitted QC: 2019-03-03
• Study First Posted: 2019-03-06
• Study Start: 2019-03-28
• Primary Completion: 2021-05-27
• Study Completion: 2021-05-27
• Status Verified: 2021-08
• Last Update Submitted: 2021-08-19
• Last Update Posted: 2021-08-20

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 25

Inclusion Criteria

1. Patients with definite CIDP diagnosed according to the modified diagnostic criteria of European Federation of Neurological Societies/Peripheral Nerve Society (EFNS/PNS) (2010) by the time of enrollment in the study

2. Patients meeting one of the following conditions:

   (i) Patients with positive serum IgG4 autoantibody (CNTN-1 or NF-155) confirmed by the time of enrollment in the study

   (ii) Patients with negative serum IgG4 autoantibody (CNTN-1 and NF-155) confirmed by the time of enrollment in the study

3. Patients with refractory CIDP not responding adequately to treatment with corticosteroid for 12 weeks, and intravenous immunoglobulin therapy (IVIg) for 8 weeks by the time of enrollment in the study, or those who are unable to administer or continue corticosteroid and IVIg

4. Patients with total adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) Disability Scale scores of 2 to 8 at both preliminary enrollment and enrollment, and with the total score at enrollment equal to or worse than that at preliminary enrollment

5. Patients aged 12 years or older at informed consent

6. Patients who give their voluntary written consent after having received adequate information on this study (legally acceptable representatives should also give consent for underage patients, and informed assent should be obtained from children aged 12 to 15)

Read More

Exclusion Criteria

1. Patients with disease meeting one of the following exclusion criteria defined in the modified EFNS/PNS diagnostic criteria (2010).

   (i) Borrelia burgdorferi infection (Lyme disease), diphtheria, drug or toxin exposure probably to have caused the neuropathy Hereditary demyelinating neuropathy

   (ii) Prominent sphincter disturbance

   (iii) Diagnosis of multifocal motor neuropathy

   (iv) IgM monoclonal gammopathy with high titre antibodies to myelin-associated glycoprotein

   (v) Other causes for a demyelinating neuropathy including POEMS syndrome, osteosclerotic myeloma, diabetic and non-diabetic lumbosacral radiculoplexus neuropathy PNS lymphoma and amyloidosis may occasionally have demyelinating features

2. Patients who have started or have increased the dose of corticosteroid for CIDP within 12 weeks prior to the enrollment

3. Patients who have started or have increased the dose of IVIg within 8 weeks prior to the enrollment

4. Patients who have underwent plasmapheresis within 8 weeks prior to the enrollment or patients with refractory disease not responding adequately to 8 weeks of plasmapheresis (plasma exchange or double-filtration plasmapheresis)

5. Patients who have started or have increased the dose of an immunosuppressant (azathioprine, cyclophosphamide, cyclosporine, mycophenolate mofetil, interferon alpha, interferon beta, etanercept, methotrexate, mitoxantrone, alemtuzumab, cladribine, tacrolimus, fingolimod) within 12 weeks prior to the enrollment

6. Patients who have underwent hematopoietic stem cell transplant prior to the enrollment

7. Patients who have used rituximab (genetical recombination) prior to the enrollment

8. Patients who have participated in another clinical study within 3 months prior to the enrollment (enrollment is allowed for those participating in a clinical study in the range of Indications or Dosage and Administration in Japan) or patients who are participating in another study

9. Patients with poorly controlled diabetes (HbA1c of 7 % or higher)

10. Patients who have or are suspected to have active infection (infection requiring treatment with systemic antimicrobial, antifungal, or antiviral agents) at the time of the enrollment

11. Patients tested positive for HBs antigen, HBs antibody, HBc antibody, and/or HCV antibody (patients with positive HBs antibody or HBc antibody can be enrolled when a hepatitis B virus-DNA test is negative [below the limit of detection], and hepatitis B virus-DNA and aspartate/alanine transaminase levels are monitored at fixed intervals), or patients with positive HIV antibody or HTLV-1 antibody at the time of the enrollment

12. Patients with leukopenia (less than 2,000 /mm3), neutropenia (less than 1,000 /mm3), or lymphopenia (less than 500 /mm3) at the time of the enrollment

13. Patients with history of serious hypersensitivity or anaphylactic reaction to one of the ingredients in the investigational drug or murine protein-containing products

14. Patients with serious comorbidity (e.g., hepatic, renal, cardiac, lung, hematologic, or brain disease)

15. Female patients who are pregnant, lactating, or potentially pregnant, or patients who are not willing to use contraceptive measures during the study period

16. Patients who are judged to be unsuitable by the investigator or a sub-investigator

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Rituximab group (IgG4 autoantibody positive)	Rituximab (genetical recombination)	-
Placebo group (IgG4 autoantibody positive)	Placebo	-
Rituximab group (IgG4 autoantibody negative)	Rituximab (genetical recombination)	-

Primary Outcome Measures

Name	Time	Method
Rate of patients with improvement in adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) disability scale	Up to 52 weeks	Primary analysis will compare scores of adjusted INCAT Disability Scale evaluated prior to treatment (at the time of enrollment) and scores at each timepoint after week 26 to calculate the proportion of patients who achieve an improvement of one and more from the baseline.; The INCAT Disability Scale is an index to evaluate disorders in lower (gait) and upper (elevation of the upper arms and fine movement of the fingertips) extremities. The INCAT score is a 10-point scale and ranges from 0 (normal) to 10 (worst). For the "adjusted" INCAT score, a change in upper extremity score from 0 to 1 or 1 to 0 will not be considered meaningful in this evaluation.

Secondary Outcome Measures

Name	Time	Method
Change in Rasch-built Overall Disability Scale (R-ODS) score	Up to 52 weeks	The differences of R-ODS score between prior to treatment and at each timepoint are summarized.; R-ODS is consist of a 24-item questionnaire about daily living task with 3 response options: (0) "impossible to perform," (1) "performed with difficulty," and (2) "easily performed. The R-ODS score is a 48-point scale (range: 0-48), and is converted into a centile metric score with values ranging from 0 (most severe activity and social participation limitations) to 100 (no activity and social participation limitations).
Change in Medical Research Council (MRC) Sum Score	Up to 52 weeks	The differences of MRC Sum Score between prior to treatment and at each timepoint are summarized.; The MRC Sum Score is a scale to assess for 8 muscle groups (right and left side) as follow: Shoulder abduction, Elbow flexion, Wrist extension, Index finger abduction, Hip flexion, Knee extension, Foot dorsiflexion, Great toe dorsiflexion.The MRC Sum Score is a 80-point scale and ranges from 0 (paralysis) to 80 (normal strength).
Change in motor nerve distal latency	Up to 52 weeks	The differences of distal latency between prior to treatment and at each timepoint are summarized.
Change in motor nerve proximal latency	Up to 52 weeks	The differences of proximal latency between prior to treatment and at each timepoint are summarized.
Cerebrospinal fluid protein level	Up to 52 weeks	Cerebrospinal fluid protein level at each timepoint are summarized.
B cell counts (CD19 positive and CD20 positive cell counts) and T cell counts (CD3 positive, CD4 positive, and CD8 positive cell counts)	Up to 52 weeks	B cell counts (CD19 positive and CD20 positive cell counts) and T cell counts (CD3 positive, CD4 positive, and CD8 positive cell counts) at each timepoint are summarized.
Serum antibody titers of IgG4 (CNTN-1 and NF-155) and these IgG subclass	Up to 52 weeks	Serum titers (CNTN-1 and NF-155, and these IgG subclasses 1 to 4) at each timepoint are summarized.
Expression of HACA	Up to 52 weeks	The number of patients expressing HACA, and the proportion and its 95% confidence interval of these patients at each timepoint are summarized.
Maximum serum concentration (Cmax) of rituximab (genetical recombination)	Up to 52 weeks	Cmax of rituximab (genetical recombination) is summarized.
Half-life (t1/2) of rituximab (genetical recombination)	Up to 52 weeks	t1/2 of rituximab (genetical recombination) is summarized.
Clearance (CL) of rituximab (genetical recombination)	Up to 52 weeks	CL of rituximab (genetical recombination) is summarized.
Mean residence time (MRT) of rituximab (genetical recombination)	Up to 52 weeks	MRT of rituximab (genetical recombination) is summarized.
Volume of distribution (Vds) of rituximab (genetical recombination) level	Up to 52 weeks	Vds of rituximab (genetical recombination) is summarized.
Serum neurofilament	Up to 52 weeks	Serum neurofilament level at each timepoint is summarized.
Change in grip strength (kPa)	Up to 52 weeks	The differences of Grip strength (kPa) between prior to treatment and at each timepoint are summarized.
Change in motor nerve compound muscle action potential (CMAP)	Up to 52 weeks	The differences of CMAP between prior to treatment and at each timepoint are summarized.
Change in motor nerve conduction velocity	Up to 52 weeks	The differences of motor nerve conduction velocity between prior to treatment and at each timepoint are summarized.
Serum rituximab (genetical recombination) level	Up to 52 weeks	Serum rituximab (genetical recombination) level at each timepoint are summarized.
Area under the curve (AUC) of blood concentration of rituximab (genetical recombination)	Up to 52 weeks	AUC of blood concentration of rituximab (genetical recombination) is summarized.

Trial Locations

Locations (4)

Nagoya University Hospital; 🇯🇵 Nagoya, Aich, Japan

Yamaguchi University Hospital; 🇯🇵 Ube, Japan

Chiba University Hospital; 🇯🇵 Chiba, Japan

Kyushu University Hospital; 🇯🇵 Fukuoka, Japan